AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19378912
Drug: Daily supine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supine cycle exercise (Exercise group; N = 14)
Trial: 17387462
Drug: Ximelagatran co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran co-administered with azithromycin
Trial: 17387462
Drug: Ximelagatran co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran co-administered with cefuroxime
Trial: 17387462
Drug: Ximelagatran co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran co-administered with amoxicillin, doxycycline, or ciprofloxacin
Trial: 9049513
Drug: Nisoldipine coat-core
RxNorm normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nisoldipine coat-core (nisoldipine-CC)
Trial: 8396103
Drug: Azithromycin, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, single daily dose of 10 mg/kg (maximum 500 mg) for three days (n = 46)
Trial: 8396103
Drug: Erythromycin ethylsuccinate,
RxNorm normalized name: Erythromycin Ethylsuccinate, ethylsuccinate compounding powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate, 30‐50 mg/kg daily in three divided doses for ten days (n = 47)
Trial: 24170106
Drug: LB03002 (once-weekly)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 (once-weekly)
Trial: 24170106
Drug: Daily GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily GH (daily)
Trial: 24170106
Drug: LB03002 (once-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LB03002 (once-weekly throughout)
Trial: 22874850
Drug: Semi-synthetic DTwP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-synthetic DTwP vaccine
Trial: 22874850
Drug: Routine DTwP
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine DTwP vaccine
Trial: 20517329
Drug: Q‐500 (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q‐500 (500 mg/day)
Trial: 20517329
Drug: Q‐1000 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q‐1000 (1000 mg/day)
Trial: 8707025
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER 10 mg o.d.
Trial: 8707025
Drug: Nifedipine AR
RxNorm normalized name: nifedipine Extended Release Oral Tablet [Adalat AR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine AR 20 mg b.d.
Trial: 1679569
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (azathioprine + sulfasalazine)
Trial: 26784000
Drug: Extended ofatumumab
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Extended ofatumumab treatment
Trial: 22558609
Drug: Palmitoylethanolamide (PEA)
RxNorm normalized name: Palmitoylethanolamide
DrugBank: Palmidrol (DB14043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitoylethanolamide (PEA) 300 mg in the morning and 600 mg in the evening for 7 days, then 300 mg twice a day for 7 more days
Trial: 22558609
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg three times a day for 2 weeks
Trial: 12679767
Drug: Tirofiban infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban infusion
Trial: 11029126
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg kg(‐1) cisatracurium
Trial: 11029126
Drug: 0.15 mg
RxNorm normalized name: iodine 0.15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg kg(‐1) cisatracurium
Trial: 1305331
Drug: 500 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 micrograms sublingual GTN
Trial: 1305331
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg buccal GTN
Trial: 31145432
Drug: Static treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static treatment protocol
Trial: 31145432
Drug: Dynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic treatment protocol
Trial: 22334369
Drug: Pioglitazone 30-45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30-45 mg/day plus standard care (peginterferon alpha-2a plus ribavirin for 48 weeks)
Trial: 20803300
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) administered twice daily, titrated from 250 to 2,000 mg/day
Trial: 17937961
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tolterodine extended release
Trial: 17937961
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg tolterodine extended release
Trial: 7800329
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (1 mg), administered at admission and repeated 6 hours later if labor was not established
Trial: 7800329
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (1 mg)
Trial: 2181769
Drug: Furosemide administered
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide administered post-TURP
Trial: 30587533
Drug: Mupirocin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin (5 days of intranasal plus topical application to the intranasal, periumbilical, and perianal areas)
Trial: 30587533
Drug: Mupirocin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin (5 days of intranasal plus topical application)
Trial: 12532318
Drug: Temazepam (7.5-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (7.5-30 mg)
Trial: 8652325
Drug: Rocuronium 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 6 mg
Trial: 8652325
Drug: Vecuronium 1
RxNorm normalized name: vecuronium 10 mg/10 mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 1 mg
Trial: 2049961
Drug: Ofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (400 mg orally once daily for 3 weeks)
Trial: 2049961
Drug: Co-trimoxazole (320/1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (320/1,600 mg orally once daily for 3 weeks)
Trial: 6388218
Drug: Danazol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (100 mg, 2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Trial: 6388218
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules a day for the first month, then 1 capsule a day up to 6 months)
Trial: 25434622
Drug: EMLA® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® cream (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) applied for 60 minutes prior to cryotherapy
Trial: 25434622
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied for 60 minutes prior to cryotherapy
Trial: 25434622
Drug: EMLA® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® cream (for those with more than 1 wart)
Trial: 25434622
Drug: EMLA® cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA® cream (for those with only 1 wart)
Trial: 23167380
Drug: Rational-Emotive Behavior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-Emotive Behavior Therapy (REBT) for 45 days (ten sessions)
Trial: 9934749
Drug: 6 million
RxNorm normalized name: INTERFERON ALFA-2A,RECOMBINANT 6 MILLION UNT/ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Trial: 9934749
Drug: 9 million
RxNorm normalized name: INTERFERON ALFA-2A,RECOMBINANT 9 MILLION UNT/SYR INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 million units (MU) of lymphoblastoid interferon alpha (IFN) daily for the first 2 weeks, then thrice weekly for an additional 14 or 22 weeks
Trial: 7594330
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg (n = 9)
Trial: 7594330
Drug: lansoprazole (LPZ)
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lansoprazole (LPZ) 30 mg (n = 16)
Trial: 7594330
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg plus plaunotol 480 mg (n = 13)
Trial: 7594330
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg plus ecabet sodium 2 g (n = 11)
Trial: 7594330
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg plus clarithromycin 600 mg (the first 2 weeks; n = 11)
Trial: 7594330
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg plus plaunotol 480 mg plus clarithromycin 600 mg (the first 2 weeks; n = 13)
Trial: 7594330
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg plus ecabet sodium 2 g plus amoxicillin 1,500 mg (the first 2 weeks; n = 13)
Trial: 23645099
Drug: Calcitriol administration
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcitriol administration (0.25 μg bid for 1 week)
Trial: 23645099
Drug: Cholecalciferol (300,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (300,000 IU single oral dose)
Trial: 20236252
Drug: 360° laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360° laser trabeculoplasty and topical betaxolol eye drops B.I.D.
Trial: 11527892
Drug: Albumin administration
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin administration on the day of oocyte retrieval
Trial: 11527892
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution (placebo control)
Trial: 18649869
Drug: Albumin administration
RxNorm normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin administration
Trial: 9085712
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg alcohol in light alcohol consumers
Trial: 9085712
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg alcohol in light alcohol consumers
Trial: 9085712
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg alcohol in moderate alcohol consumers
Trial: 9085712
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg alcohol in moderate alcohol consumers
Trial: 9085712
Drug: 0.5 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g/kg and 1.0 g/kg alcohol in light consumers (frequency and duration measures)
Trial: 9085712
Drug: 1.0 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g/kg alcohol in moderate consumers (duration measure)
Trial: 7942724
Drug: 1 week
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 week of quadruple therapy
Trial: 7942724
Drug: 2 weeks
RxNorm normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 weeks of quadruple therapy
Trial: 2598985
Drug: CI-924 (CI)
RxNorm normalized name: CI 77266
DrugBank: Carbon black (DB11980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CI-924 (CI) 600 mg/day
Trial: 788733
Drug: Synthetic isoquinoline
RxNorm normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic isoquinoline compound (U.K. 2371)
Trial: 22765645
Drug: High-dose levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose levofloxacin 750 mg intravenously once daily, followed by the same dose orally at discharge when clinically improved.
Trial: 22765645
Drug: Ceftriaxone 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2.0 g intravenously once daily plus oral azithromycin 500 mg for 3 consecutive days, followed by oral cefpodoxime 200 mg per day at discharge after clinical improvement.
Trial: 22765645
Drug: High-dose levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose levofloxacin
Trial: 7740334
Drug: Combined doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined doxorubicin (50 mg/m2 day 1) and vinorelbine (25 mg/m2 days 1 and 8) every 21 days
Trial: 2258080
Drug: Carboplatin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (400 mg/m2 IV every 28 days)
Trial: 11326179
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 3 mg (group 1)
Trial: 30678863
Drug: Mineralocorticoid Receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid Receptor Antagonists (MRA)
Trial: 27043452
Drug: MP‐AzeFlu (Dymista(®),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP‐AzeFlu (Dymista(®), 1 spray/nostril bid)
Trial: 27043452
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP, 1 spray/nostril bid)
Trial: 24281730
Drug: Montelukast (monotherapy)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (monotherapy)
Trial: 24281730
Drug: Antihistamine (monotherapy)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (monotherapy)
Trial: 23200287
Drug: Mentalization-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mentalization-based treatment for adolescents (MBT-A)
Trial: 18097903
Drug: Obstetric fistulae
RxNorm normalized name: Cassia fistula whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obstetric fistulae treatment
Trial: 15800937
Drug: Quetiapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (up to 200 mg daily)
Trial: 12450694
Drug: Urease (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urease (60 mg) + LT (5 microg)
Trial: 12450694
Drug: Urease (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urease (60 mg) + LT (25 microg)
Trial: 12450694
Drug: Urease (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urease (60 mg)
Trial: 366085
Drug: Bromocriptine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (30 mg per day in divided doses)
Trial: 27880079
Drug: Intravenous erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous erythromycin (3 mg/kg)
Trial: 23615650
Drug: Watermelon supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon supplementation (L‐citrulline/L‐arginine 6 g/d)
Trial: 20077977
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi (intervention not specified in dosage or duration)
Trial: 12601628
Drug: Troglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone treatment in Group A
Trial: 12601628
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in Group B
Trial: 12601628
Drug: Troglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone treatment in Groups B and C
Trial: 12601628
Drug: Troglitazone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone treatment in all groups
Trial: 10553828
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg (2 mL 1.5%)
Trial: 10553828
Drug: 45 mg
RxNorm normalized name: lutein 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 mg (3 mL 1.5%)
Trial: 10553828
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg (4 mL 1.5%)
Trial: 30457668
Drug: Citicoline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline (titrated to 2,000 mg/d)
Trial: 29132478
Drug: Vaginal clindamycin
RxNorm normalized name: clindamycin Vaginal Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal clindamycin (multiple doses)
Trial: 29132478
Drug: Oral secnidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral secnidazole (single 2-gm dose)
Trial: 21554817
Drug: Whole-grain wheat
RxNorm normalized name: rice (whole grain) allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-grain wheat (48 g daily for 3 weeks)
Trial: 10685531
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg/d) on days 3-7 of the CC-treated cycles
Trial: 9692707
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg daily; n = 8)
Trial: 9692707
Drug: Ranitidine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (300 mg b.d.; n = 6)
Trial: 9692707
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (before treatment; n = 24)
Trial: 25760389
Drug: 5% glycolic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glycolic plant extract applied externally (gel cream) for 21 days
Trial: 24351403
Drug: Placebo (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (no active treatment)
Trial: 20099236
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination latanoprost-timolol (n = 170)
Trial: 20099236
Drug: Latanoprost monotherapy
RxNorm normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Latanoprost monotherapy (n = 165)
Trial: 20099236
Drug: Timolol monotherapy
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol monotherapy (n = 165)
Trial: 18402906
Drug: SR123781A 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR123781A 0.25 mg
Trial: 18402906
Drug: SR123781A 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR123781A 0.5 mg
Trial: 18402906
Drug: SR123781A 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR123781A 1.0 mg
Trial: 18402906
Drug: SR123781A 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR123781A 2.0 mg
Trial: 18402906
Drug: SR123781A 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR123781A 4.0 mg
Trial: 18402906
Drug: Enoxaparin 40
RxNorm normalized name: ENOXAPARIN 40MG/0.4ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin 40 mg (calibrator arm)
Trial: 12386357
Drug: Intratubal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intratubal methotrexate 1 mg/kg
Trial: 10458218
Drug: Vorozole (VOR)
RxNorm normalized name: vorozole
DrugBank: Vorozole (DB13767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vorozole (VOR) 2.5 mg once daily
Trial: 10458218
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 40 mg four times per day
Trial: 7605361
Drug: Kwai garlic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kwai garlic powder tablets 300 mg three times daily
Trial: 7119301
Drug: Budesonide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (various doses), morning dosing
Trial: 7119301
Drug: Budesonide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (various doses), reduced dose frequency
Trial: 27060731
Drug: Intervention manipulations
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention manipulations (either of the intervention manipulation or combination)
Trial: 22406033
Drug: Sleep hygiene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep hygiene therapy
Trial: 17947598
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition (0.2 g/kg/d of nitrogen and 30 nonprotein kcal/kg/d)
Trial: 17947598
Drug: Standard hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard hospital oral diet (control group)
Trial: 15939923
Drug: Fluorouracil (FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FU) 2.6 g/m(2) and folinic acid (FA) 500 mg/m(2) weekly for 6 weeks followed by a 2-week rest (AIO arm, n = 216)
Trial: 15939923
Drug: Fluorouracil (FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (FU) 2.3 or 2.0 g/m(2) preceded by irinotecan 80 mg/m(2) administered over 30 minutes weekly for 6 weeks followed by a 2-week rest (experimental group, n = 214)
Trial: 10456819
Drug: Single-injection paravertebral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection paravertebral block at the level of T4
Trial: 2357777
Drug: Intravenous potassium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous potassium chloride (Group I, 44 patients)
Trial: 2357777
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline (Group II, 48 patients)
Trial: 2357777
Drug: Oral potassium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral potassium chloride capsules (Group III, 50 patients)